Inverness Counsel’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
Other funds holding REGN
Inverness Counsel's REGN Position: Q3 2022 in Review
Inverness Counsel increased its Regeneron Pharmaceuticals (REGN) stake by 7.4% in Q3 2022, buying an estimated $36.5K and bringing the position to 842 shares worth $580K. The position accounts for 0.03% of the portfolio, ranked #114.
Inverness Counsel first reported a position in REGN in Q3 2021 and has held it in 5 quarters since. 1,081 funds tracked by Wall St. Rank hold REGN as of Q3 2022.
- Inverness Counsel held 842 shares of Regeneron Pharmaceuticals worth $580K as of Q3 2022.
- Inverness Counsel bought 58 Regeneron Pharmaceuticals shares in Q3 2022, an estimated $36.5K.
- Regeneron Pharmaceuticals made up 0.03% of Inverness Counsel's portfolio in Q3 2022, its #114 holding.
- Inverness Counsel first reported a position in Regeneron Pharmaceuticals in Q3 2021 and has held it in 5 quarters since.
- 1,081 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2022.
Based on Inverness Counsel's 13F filing for Q3 2022, filed 26 Oct 2022.